Business Context and Reporting Period
This Form 8-K Current Report was filed by LeMaitre Vascular, Inc. (LMAT) on February 13, 2025, covering events occurring on February 7, 2025. The filing discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $565,000 annually.
- Target Bonus: $225,000 annually (discretionary).
- Annual Equity Award: $375,000 (four-year vesting).
- One-Time Equity Award: $100,000 in restricted stock units (four-year vesting).
Material Changes
The primary material change is the appointment of Dorian LeBlanc as Chief Financial Officer and principal financial officer, effective March 10, 2025. Mr. LeBlanc joins from LumiraDx Limited (recently acquired by Roche), where he served as CFO and COO. The filing confirms no other material transactions involving the new officer exceeding $120,000 have occurred since the beginning of the last fiscal year.
Outlook, Risks, and Contingencies
The filing outlines specific severance contingencies in the event of termination without cause:
- Termination on or before March 10, 2028: Lump sum payment of $100,000.
- Termination after March 10, 2028: The greater of two weeks of base salary per completed year of service or $225,000.
These payments are subject to the execution of a non-disparagement agreement and release. The filing does not contain forward-looking guidance on business operations or financial performance.
Investor Verification Checklist
- Verify the effective start date of March 10, 2025, for the new CFO.
- Review the full Offer Letter (Exhibit 10.1) for detailed vesting schedules and performance metrics.
- Confirm the transition plan for the outgoing CFO, Joseph P. Pellegrino, Jr., who signed the report.
- Assess the impact of the new compensation package on future operating expenses.